Bradykinin (BK) is a peptide mediator generated at sites of inflammation and its effects are mediated through constitutively expressed B 2 receptor or through induction of B 1 receptors. We examined the role of these receptors in bronchial hyperresponsiveness (BHR). Brown-Norway rats sensitized with ovalbumin (OA) and Al(OH) 3 intraperitoneally, were exposed 3 wk later to either saline or OA aerosol. B 1 receptor antagonist desArg 
Bradykinin (BK) is a peptide mediator generated at sites of inflammation and its effects are mediated through constitutively expressed B 2 receptor or through induction of B 1 receptors. We examined the role of these receptors in bronchial hyperresponsiveness (BHR). Brown-Norway rats sensitized with ovalbumin (OA) and Al(OH) 3 intraperitoneally, were exposed 3 wk later to either saline or OA aerosol. B 1 receptor antagonist desArg 10 [Hoe140] (200 nmol/kg or 1 mol/kg, intraperitoneally) or B 2 receptor antagonist Hoe140 (200 nmol/kg, intraperitoneally) was administered 30 min before allergen exposure. Hoe140 had no effect on OA-induced BHR to acetylcholine (ACh) and bronchoalveolar lavage fluid (BALF) cellular profiles, but inhibited bronchoconstriction to BK (p Ͻ 0.04). At both doses, desArg 10 [Hoe140] dose-dependently inhibited allergen-induced BHR to ACh (p Ͻ 0.01), but had no effect on bronchoconstriction to BK or baseline ACh responsiveness. The inflammatory cells in BALF were not affected apart from reduced lymphocyte numbers at the highest dose. B 1 receptor mRNA expression measured by Northern analysis was increased after allergen exposure in sensitized lungs, with a peak at 2 to 6 h after exposure, whereas B 2 receptor mRNA expression remained unchanged. Newly induced BK B 1 receptors may be involved in allergen-induced BHR to ACh, whereas constitutive B 2 Bradykinin (BK) is a peptide mediator that is formed during inflammation and tissue injury and there is evidence to suggest it plays a key role in the airway inflammation of asthma. For example, kinin activity has been measured in bronchoalveolar lavage fluid (BALF) from asthmatic subjects at rest and after allergen challenge (1, 2) . BK itself is a potent bronchoconstrictor in asthmatic subjects (3, 4) and mediates the nasal blockage observed in patients with allergic rhinitis after allergen challenge (5) . In animals, BK has been shown to have important effects in the lung including bronchoconstriction, plasma exudation, vascular dilatation, and sensitization of airway afferents (6) (7) (8) . Two distinct receptors have been identified pharmacologically and through molecular cloning, termed B 1 and B 2 (9) . Most of the biological activities of BK are mediated through the activation of constitutively expressed B 2 receptors (10) . By contrast, B 1 receptors are not present in tissue under "normal" conditions, but are induced during inflammatory insults and after exposure to noxious stimuli (11) (12) (13) . For example, functional and radioligand binding studies have demonstrated the appearance of B 1 receptors in tissues such as vascular and gastrointestinal smooth muscle, as well as in isolated cells including macrophages, platelets, vascular smooth muscle, and endothelial cells after exposure to lipopolysaccharide (LPS) or interleukin (IL)-1 ␤ (12-15). Stimulation of B 1 receptors elicits a variety of effects including vascular smooth muscle contraction and relaxation, prostanoids and interleukin-1 (IL-1) release, and increase in intracellular calcium level (14) (15) (16) (17) . Although stimulation of B 1 receptors with B 1 receptor agonists has no effect on airway tone in patients with asthma (4, 18) , this caused a relaxant effect in isolated murine tracheal rings in vitro (19, 20) .
Despite these observations, there still remain uncertainties regarding the functional role of BK B 1 receptors in the airways, particularly in terms of their role in bronchial hyperresponsiveness (BHR). In allergen-induced BHR, both B 1 and B 2 receptors have been implicated in the guinea pig (21) , but in that study, modulation of these receptors after allergen challenge was not examined. We therefore determined whether BK B 1 and B 2 receptors are regulated after allergen exposure in sensitized rats, and their roles in allergen-induced BHR and bronchial inflammation were investigated. Thus, we examined the effect of a BK B 2 receptor antagonist, D-Arg[Hyp 
METHODS

Animals, Sensitization Procedures, and Allergen Exposure
Pathogen-free inbred male Brown-Norway rats (Harlan Olac Ltd., Bicester, UK) (200 to 250 g, 9 to 13 wk old) kept in identical conditions were injected with 1 ml of 1 mg ovalbumin (OA) (Grade V, saltfree; Sigma, Dorset, UK) in 100 mg Al(OH) 3 (BDH, Dorset, UK) suspension in 0.9% (wt/vol) saline intraperitoneally on three consecutive days. Challenge with saline or OA aerosol exposure to rats was performed 21 d later. The animals were then placed in a 6.5-L Plexiglas chamber connected to a DeVilbiss PulmonSonic nebulizer (model No. 2511; DeVilbiss Health Care, U.K. Ltd., Middlesex, UK) that generated an aerosol mist of OA (1% wt/vol in 0.9% NaCl) pumped into the exposure chamber by the airflow supplied by a small animal ventilator (Harvard Apparatus Ltd., Kent, UK; 60 strokes/min; pumping volume, 10 ml). The exposure time was 15 min.
Expression of B 1 and B 2 Receptor Messenger RNA (mRNA)
We first examined the time-course of possible changes in the expression of B 1 and B 2 receptor mRNA in the following groups of rats: ( 1 ) naive: nonsensitized, saline-challenged, and killed 2 h later (n ϭ 3).
( 2 ) SS: sensitized, saline-challenged, and killed at 2, 6, 12, and 24 h after challenge (n ϭ 2 to 3 at each time point). ( 3 ) SO: sensitized, OAchallenged, and killed at 2, 6, 12, and 24 h for B 1 , and 2, 8, 24, 48, and 96 h after challenge for B 2 receptor mRNA expression (n ϭ 2 to 3 at each time point).
Rats were killed with a lethal dose of pentobarbital sodium (Expiral; Sanofi Animal Health Ltd., Herts, UK; 200 mg/kg, intraperitoneally) and lung tissues were collected for Northern blot analysis.
mRNA Analysis by Northern Blot Analysis
The lungs were cut into small cubes and snap-frozen in liquid nitrogen, and stored at Ϫ 80 Њ C for later assays for mRNA expression. Total RNA from lung tissue was extracted according to the method of Chomczynski and Sacchi (22) , and mRNA was isolated using PolyATract mRNA isolation system kit (Promega, Southampton, UK). mRNA was size-fractionated on a 1% agarose/formaldehyde gel containing 20 mM morpholinosulfonic acid, 5 mM sodium acetate, and 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 7.0) and blotted onto Hybond-N membranes (Amersham, Middlesex, UK). Rat B 1 and B 2 receptor complementary DNA (cDNA) from recently cloned sequences of these receptors (23) and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 309-bp cDNA were labeled in random priming using [ ␣ -32 P]deoxycytidine triphosphate (dCTP) (3,000 Ci/mmol; Amersham). The GAPDH cDNA was a 309-bp fragment amplified from reverse transcriptase (RT)-generated cDNA corresponding to rat GAPDH. Prehybridization and hybridization were carried out at 42 Њ C with labeled probes (approximately 1.5 ϫ 10 6 counts per minute [cpm]/ml) in buffer containing 5 ϫ Denhardt's solution, 5 ϫ standard saline citrate (SSC), 50 mM TRIS-HCl (pH 7.5), 0.1% sodium dodecyl sulfate (SDS), 250 l/ml sonicated denatured salmon sperm DNA, and 50% formaldehyde. After hybridization, each blot was washed to a stringency of 0.1 ϫ SSC/0.1% SDS for 30 min at 60 Њ C and exposed for 1 to 14 d to Kodak X-OMAT S film. Autoradiographic bands were quantified by laser densitometry (Quantity One software; PDI, New York, NY). BK B 1 or B 2 receptor mRNA expression was expressed as a ratio of GAPDH mRNA expression.
Effect of B 1 Receptor Antagonist on BHR
We studied five groups of animals to investigate the effects of B 1 antagonist desArg 10 [Hoe140] (Peninsula, Merseyside, UK) on BHR: ( 1 ) Sensitized and saline-exposed animals (group SS, n ϭ 8): Sensitized rats were injected with 0.9% saline 1 ml/kg intraperitoneally (control), and were exposed 30 min later to 0.9% NaCl aerosol. ( 2 ) Sensitized, OA-exposed animals (SO, n ϭ 8): Sensitized animals were injected with 0.9% saline intraperitoneally (control), and 30 min later were exposed to 1% OA aerosol for 15 min. ( 3 ) Sensitized, saline-exposed, and BK B 1 antagonist-treated animals (SSB1, n ϭ 10): The procedures were similar as for the SS group, apart from injection of desArg 10 [Hoe140] 200 nmol/kg intraperitoneally 30 min before exposure to 0.9% NaCl aerosol. ( 4 ) Sensitized, OA-exposed, and BK B 1 antagonist-treated animals (SOB1a, n ϭ 7): The procedures were similar as for the SSB group, except that the aerosol exposure was to 1% OA. ( 5 ) Sensitized, OA-exposed, and BK B 1 antagonist-treated animals (SOB1b, n ϭ 6): The procedures were the same as for the SOB1a group, but the dose of BK B 1 antagonist was 1 mol/kg. In all groups, BHR to acetylcholine (ACh) and bronchoconstriction to BK were examined 18 to 24 h after exposure to either 1% OA or 0.9% NaCl aerosol.
Effect of B 2 Receptor Antagonist on BHR
We studied the effects of BK B 2 receptor antagonist in four groups of rats: ( 1 ) Sensitized and saline-exposed animals (Group SS, n ϭ 10): As previously defined in B 1 study. ( 2 ) Sensitized, OA-exposed animals (SO, n ϭ 8): As previously defined. ( 3 ) Sensitized, saline-exposed, and BK B 1 antagonist-treated animals (SSB2, n ϭ 6): The procedures were the same as in Group SSB1, but the injection 30 min before OA aerosol exposure was B 2 -specific antagonist Hoe140, 200 nmol/kg. ( 4 ) Sensitized, OA-exposed, and BK B 2 antagonist-treated animals (SOB2, n ϭ 8): All the procedures were the same as in Group SOB1a, except the injection before aerosol exposure of Hoe140, 200 nmol/kg.
Measurement of Bronchial Responsiveness to ACh and of Bronchoconstriction to BK
Rats were anesthetized with an intraperitoneal injection of 2 mg/kg midazolam (Roche Products Ltd., Welwyn Garden City, UK) and a subcutaneous injection of 0.4 mg/kg Hypnorm (Janssen Pharmaceuticals Ltd., Wantage, UK), which contains 0.315 mg/ml of fentanyl citrate and 10 mg/ml of fluanisone. A tracheal cannula (1.02 mm outer diameter) was inserted into the lumen of the cervical trachea through a tracheostomy. The animals were connected to a small-animal respirator (Harvard Apparatus, Edenbridge, Kent, UK) and ventilated with 10 ml/kg of air at a rate of 90 strokes/min. Transpulmonary pressure was measured with a pressure transducer (model FCO 40 Ϯ 1,000 mm H 2 O; Furness Controls, Bexhill, Sussex, UK) with one side attached to an air-filled catheter inserted into the right pleural cavity and the other side attached to a catheter connected to a side port of the intratracheal cannula. Airflow was measured with a pneumotachograph (model F1L; Mercury Electronics, Glasgow, Scotland) connected to a transducer (model FCO 40 Ϯ 20 mm H 2 O; Furness Controls). The signals from the transducers were digitized with a 12-bit analogto-digital board (NB-MIO-16; National Instruments, Austin, TX) connected to a Macintosh II computer (Apple Computer, Cupertino, CA) and analyzed with software (Lab VIEW 2; National Instruments, Austin, TX) that was programmed to measure lung resistance (R L ) according to the method of von Neergard and Wirz (36) . Aerosols were generated with an ultrasonic nebulizer (model 2511; PulmoSonic, DeVilbiss, Hazeltown, PA).
Animals were initially injected with propranolol (Inderal; Zeneca, Cheshire, UK; 1 mg/kg, intravenously) to block adrenergic effects and suxamethonium (Antigen Pharmaceuticals Ltd., Roscrea, Ireland) to stop spontaneous breathing. Baseline R L was determined after inhalation of 0.9% saline aerosol (45 breaths of 10 ml/kg stroke volume at 90 strokes/min). Then, aerosols generated from increasing half-log 10 concentrations of ACh (acetylcholine chloride; Sigma, Dorset, UK) were administered by inhalation with the initial concentration of 10 Ϫ 4 mol/L, increasing by half-log concentrations until concentration of 10 Ϫ 1 mol/L or the concentration resulting in more than 400% increase in R L above baseline. Each concentration was administered for 45 breaths. The concentration of ACh needed to increase R L 300% above baseline (PC 300 ) was calculated by interpolation on the log concentration-lung resistance curve.
After measurements of airway responsiveness to ACh, the animal was kept on the ventilator for 1 to 2 h to allow recovery from ACh effect before measurement of bronchial responsiveness to BK. When transpulmonary pressure was restored to baseline values, the animal was injected with BK B 1 receptor agonist desArg 9 -BK (30 nmol/kg; Peninsula, Merseyside, UK) to determine whether there was any bronchoconstrictor effects mediated through the BK B 1 receptor. Ten minutes later, 0.9% NaCl aerosol was inhaled again to determine the baseline R L for measurement of bronchoconstriction to BK, then 1 mM BK (Sigma, Dorset, UK) aerosol was administered for 45 breaths. The maximal percentage increase in R L above the baseline value was recorded as the bronchoconstrictor response to BK.
Bronchoalveolar Lavage (BAL) and Cell Counting
This is also described in detail elsewhere (24) . Briefly, after an overdose of anesthetics, rats were lavaged with total 20 ml 0.9% sterile saline in 2-ml aliquots via the endotracheal tube. Total cell counts were determined using Kimura stain in a Neubauer chamber under an optical microscope (Olympus BH2; Olympus Optical Company Ltd., Tokyo, Japan). Differential cell counts from cytospin preparations stained by May-Grünwald stain were counted with at least 500 cells identified as macrophages, eosinophils, lymphocytes, and neutrophils according to standard morphology under ϫ 400 magnification.
Materials
Sodium pentobarbital (Expiral) was purchased from Sanofi Animal Health Ltd., Herts, UK. Hoe140 was a gift from Hoechst AG, Frankfurt, Germany. DesArg 10 [Hoe140] and rat BK B 1 and B 2 receptor cDNA probes were kindly provided by Dr. P. McIntyre, Novartis Institute for Medical Research, London, UK.
Statistical Analysis
Data were presented as mean Ϯ SEM. For multiple comparison of different groups, the Kruskall-Wallis test for analysis of variance (ANOVA) was used. If the Kruskall-Wallis test for ANOVA was significant, we then used the Mann-Whitney U test for comparison between two individual groups. The data analysis was performed using SPSS for Windows statistical software package (SPSS Inc., Chicago, IL). A p value of Ͻ 0.05 was considered to be significant.
RESULTS
Expression of BK B 1 and B 2 Receptor mRNA B 1 receptor mRNA expression was increased in sensitized animals challenged with OA, with a peak of expression 2 to 6 h after challenge. B 1 mRNA was not changed in sensitized animals challenged with saline. Concentrations of B 2 mRNA were Expression of B 1 receptor mRNA in OA-sensitized and challenged animals peaked at 2 to 6 h and remained higher at 24 h after OA aerosol exposure when compared with baseline naive animals. There was no change in B 2 receptor mRNA expression in saline-or allergen-exposed rats. h ϭ hour; N ϭ naive; SS ϭ sensitized and saline-exposed; SO ϭ sensitized and OA-exposed.
unaffected by sensitization or challenge with OA compared with naive animals (Figure 1) . , respectively, for the five groups studied. There was no significant difference between the five groups. The allergen-induced BHR to ACh in the sensitized animal challenged with OA was reflected in significantly greater R L responses at ACh concentrations of 10 Ϫ2.5 , 10
Ϫ2
, and 10 Ϫ1.5 M, compared with animals challenged with saline (Figure 2A) , and also in greater mean ϪlogPC 300 (p Ͻ 0.005, Figure 2B ). Treatment of sensitized and OA-exposed rats with desArg 10 [Hoe140] dose-dependently attenuated bronchial responsiveness, with ϪlogPC 300 at 1.76 Ϯ 0.05 and 1.54 Ϯ 0.1 M after the 0.2 and 1 mol/kg doses, respectively, while having no effect on bronchial responsiveness to ACh in animals challenged with saline (Figures 2A and 2B) .
Bronchoconstriction to BK. OA-sensitized animals exposed to OA aerosol had a significantly greater response to BK than OA-sensitized, saline-exposed rats (51.9 Ϯ 7.5 versus 203.4 Ϯ 27.7%; p Ͻ 0.01). The B 1 antagonist desArg 10 [Hoe140] had no significant effect on the bronchoconstriction to BK (Figure 3) . Administration of the B 1 agonist desArg 9 -BK before measurement of bronchoconstriction to BK had no significant effect on the baseline R L measurements (data not shown).
To exclude the possibility that the effect of the B 1 antagonist desArg 10 [Hoe140] may have worn off by the time the BK challenge was performed, we injected in a separate group of allergen-exposed sensitized rats (n ϭ 6) two doses of the antagonist (200 nmol/kg intraperitoneally each) at 30 min before allergen exposure, and 18 to 24 h later after the termination of ACh challenge. BK challenge was then performed 30 min later. Controls were allergen-exposed, sensitized rats (n ϭ 6) but treated with 0.9% NaCl administered intraperitoneally. Control rats demonstrated a 180.8 Ϯ 18.4% increase in R L after exposure to BK, and treatment with desArg 10 [Hoe140] did not cause a significant change in the bronchoconstrictor response to BK (147.5 Ϯ 12.6). There was a significantly reduced bronchial responsiveness in the desArg 10 [Hoe140]-treated rats (Ϫlog PC 300 in saline-treated: 1.96 Ϯ 0.09, and in desArg 10 [Hoe140]-treated: 1.34 Ϯ 0.04; p Ͻ 0.005). BAL cell profile. Total cell number and numbers of macrophages were not significantly different in sensitized, OAexposed rats, compared with sensitized, saline-exposed rats. However, the numbers of eosinophils, lymphocytes, and neutrophils increased significantly in the sensitized and OA-challenged SO group (p Ͻ 0.01). Treatment with desArg 10 [Hoe140] did not alter the numbers of eosinophils and neutrophils, although at the higher dose (1 mol/kg), it produced a decrease in lymphocyte numbers after OA challenge (p Ͻ 0.05 compared with the SS group; Figure 4 ).
Effect of BK B 2 Receptor Antagonist Hoe140
There was no significant effect of Hoe140 on allergen-induced increase in ϪlogPC 300 in sensitized rats ( Figure 5 ). However, Hoe140 significantly reduced bronchoconstriction to BK in sensitized rats and attenuated OA-induced BHR to BK (p Ͻ 0.03 for SSB2 versus SS group; p Ͻ 0.04 for SOB2, compared with SO group; Figure 6 ). Hoe140 had no effect on the inflammatory cell recruitment in BALF caused by OA sensitization and exposure (Figure 7) .
DISCUSSION
We have shown for the first time an increase in B 1 receptor expression in the lungs of sensitized rats during airway inflammation induced by an allergen. OA challenge in sensitized animals induced an increase in B 1 mRNA concentrations with no change in B 2 mRNA levels. As previously described in this Brown-Norway rat model (24) , exposure to OA induced BHR to ACh and bronchoconstriction to BK, and increased the numbers of eosinophils, neutrophils, and lymphocytes recovered in BALF. Pretreatment with a BK B 1 receptor antagonist prevented OA-induced BHR to ACh, and produced a small reduction in lymphocyte numbers. The B 2 receptor antagonist did not affect BHR to ACh but inhibited BK-induced bronchoconstriction. These results indicate that release of BK after allergen exposure may activate both BK B 1 and B 2 receptors, with B 1 receptors involved in induction of nonspecific BHR, whereas B 2 receptors but not B 1 , as would be expected, are necessary for the transduction of BK-induced bronchoconstriction.
The majority of the bronchial effects of BK so far described are mediated through the activation of B 2 receptors. Using B 2 receptor antagonists, B 2 receptors have been shown to mediate BK-induced bronchoconstriction, airway microvascular leakage, mucus secretion, and excitation and sensitization of sensory fibers (6, 7, 25) . These activities do not appear to involve B 1 receptors. In Brown-Norway rat lung membranes, we found exclusively binding sites for B 2 receptors in rat lung membrane with no evidence of B 1 -binding sites using radioligand binding studies (26) . The present study confirmed these findings, showing significant expression of B 2 mRNA in normal rat lung, but no detectable B 1 receptor mRNA. However, after allergen challenge, B 1 receptor mRNA expression is induced, whereas levels of B 2 receptor mRNA remain unchanged. The changes in receptor mRNA are mirrored by the effect of the B 1 and B 2 receptor antagonists that inhibited allergen-induced BHR to ACh and to BK, respectively. By contrast, IL-1␤-or ozone-treated rats do not demonstrate augmentation of mRNA expression of either B 1 or B 2 receptors (26, 27) , and in the IL-1␤-exposed rats, an increase in bronchoconstriction to BK, which was mediated by B 2 receptors, was observed without BHR to ACh (26, 28) .
The dose of B 2 antagonist Hoe140 was selected according to previous studies (25, 29, 30) . We used a dose of Hoe140 that was higher than that used previously in order to achieve effective levels during the 24 h after allergen challenge in the present study. Inhibition of BK-induced bronchoconstriction by Hoe140 at 24 h indicates that the dose was effective. Hoe140 was also able to inhibit the bronchoconstriction induced by BK in rats exposed to allergen, although this inhibition was not as effective as that observed in the saline-challenged rats. There is relatively less information regarding the pharmacokinetic property of desArg 10 [Hoe140], which was used as a B 1 receptor antagonist. DesArg 10 [Hoe140] is a derivative of Hoe140 and shares the same metabolic stability of Figure 4 . BAL fluid cellular profiles in B 1 antagonist study. BAL was performed with 20 ml 0.9% saline in 2-ml aliquots via endotracheal tube. Total cell counts were determined using Kimura stain in a Neubauer chamber under an optical microscope. Differential cell counts from cytospin preparations stained by MayGrünwald stain were counted with at least 500 cells identified as macrophages, eosinophils, lymphocytes, and neutrophils according to standard morphology under ϫ400 magnification. Mac ϭ macrophages; Eos ϭ eosinophils; Lym ϭ lymphocytes; Neu ϭ neutrophils. *p Ͻ 0.01 compared with SS and SSB groups; **p Ͻ 0.04 compared with SO group.
Hoe140 but has a relatively higher affinity for B 1 receptors (31) . Although the selectivity of this antagonist for B 1 receptor is not large, our data indicate that most of the effects shown were mediated through the B 1 receptor. Thus, while there was a dose-dependent inhibition of OA-induced BHR by desArg 10 [Hoe140], there was no effect of Hoe140. In addition, we showed that desArg 10 [Hoe140] at the highest dose used, together with an additional dose administered 30 min before BK challenge, did not interfere with BK-induced bronchoconstriction that is mediated through B 2 receptor. This also indicated that there was no contribution of BK B 1 receptor in the bronchoconstrictor response to BK, even after allergen challenge. In addition, we found no bronchoconstrictor effect of the B 1 agonist des-Arg 9 -BK, even after allergen challenge. Our results are similar to those observed in asthmatic patients in whom B 1 agonists do not induce bronchoconstriction (4, 18) . Thus, our data indicate that B 1 receptors are involved in allergen-induced BHR, whereas B 2 receptors mediate BKinduced bronchoconstriction.
The mechanisms by which induced B 1 receptors play a role in OA-induced BHR are unclear. Stimulation of B 1 receptors can elicit a variety of effects including vascular smooth muscle contraction and relaxation, prostanoid and IL-1 release from macrophages, and increase in intracellular calcium (14) (15) (16) (17) . A possible role of BK B 1 receptors on nerve endings has been postulated for chemotaxis of neutrophils (32) . However, upregulated B 1 receptors do not appear to be involved in recruitment of inflammatory cells as the number of eosinophils and neutrophils in BAL fluid remained unchanged. However, the reduction in lymphocyte numbers may indicate some inhibition of T-cell regulation. In the Brown-Norway rat model, we have previously shown that there is an increase in expression of the mRNA for T-helper (Th2)-derived cytokines, IL-4, and IL-5 in the lung after allergen challenge (33) , raising the possibility of B 1 receptor antagonists affecting Th2-cell activation. Although B 1 receptors do not appear to mediate bronchoconstriction, they may increase the responsiveness of airway smooth muscle through modulation of neural pathways. In the thermal hyperalgesia model in the rat, BK B 1 receptors were expressed, activation of which produced significant hyperalgesia, possibly on the nociceptive terminal itself (34) . Other mechanisms may involve increased cytokine release from macrophages as has been previously shown (16) . Information on the localization of B 1 receptors in the airways of allergen-exposed rats would be useful in determining the mechanisms involved.
Our results are somewhat at variance with those reported in other species. In the sheep, a B 2 receptor antagonist, NPC 567, inhibited Ascaris suum-induced BHR to carbachol and BK, neutrophil influx and release of leukotriene B4 and C4, and various products of the cyclooxygenase pathway in sheep (35) . Another B 2 receptor antagonist had a small inhibitory effect on the BHR to histamine in guinea pigs after a single exposure to OA, but there was greater inhibitory effect of a B 1 receptor antagonist, des-Arg ]-BK, against BHR to histamine and the neutrophilia in BALF (21) . It is possible that these different results may result from species difference in the expression of B 1 receptors after allergen exposure.
In conclusion, BK B 1 receptors can be induced by OA exposure in OA-sensitized rats, and play a role in the induction of OA-induced BHR to ACh; in contrast, BK B 2 receptors are constitutively expressed and mediate the bronchoconstrictor effect of BK. Further studies are needed to elucidate the mechanisms of B 1 receptor upregulation by allergen exposure and those by which B 1 receptors lead to nonspecific BHR.
